Agios Pharmaceuticals (AGIO) Share-based Compensation (2012 - 2026)

Agios Pharmaceuticals has reported Share-based Compensation for 15 years, with the latest figure at $15.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 36.82% year-over-year to $15.5 million; the trailing twelve-month figure through Mar 2026 stood at $56.7 million (up 26.15% YoY), and the FY2025 full-year result was $52.6 million, up 22.65% from the prior year.
• Share-based Compensation for Q1 2026 stood at $15.5 million, up from $14.1 million in the prior quarter.
• The five-year high for Share-based Compensation was $15.5 million in Q1 2026, with the low at $9.1 million in Q3 2023.
• Historically, Share-based Compensation has averaged $12.1 million across 5 years, with a median of $11.5 million in 2022.
• Annual changes were most pronounced in 2023 — Share-based Compensation sank 34.63% — and 2026, when it soared 36.82%.
• Agios Pharmaceuticals' Share-based Compensation stood at $11.5 million in 2022, then rose by 20.49% to $13.8 million in 2023, then decreased by 21.07% to $10.9 million in 2024, then climbed by 29.54% to $14.1 million in 2025, then rose by 10.03% to $15.5 million in 2026.
• The last three Share-based Compensation figures came in at $15.5 million (Q1 2026), $14.1 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.